Outcomes of surgical treatment of advanced gastrointestinal stromal tumors


Cite item

Full Text

Abstract

Targeted therapy of imatinib is a standard treatment of patients with metastatic gastrointestinal stromal tumors (GIST). The role of surgical approach in treatment of patients with disseminated GIST is remaining the most important and controversial issues. The retrospective analysis of the treatment of 140 patients with disseminated GIST to assess the efficacy of surgical treatment was carried out. Surgical treatments in combination with targeted therapy were performed in 98 patients and 42 patients were treated using only tyrosine kinase inhibitors.Comparative analysis showed the statistically significant improvement of remote results in the group of patients undergoing surgical operations associated with the effect of therapy using tyrosine kinase inhibitors. Cytoreductive surgery in patients with diffuse progression on imatinib therapy does not improve survival rates.

About the authors

O B Abouhaidar

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: abouhaidar@yandex.ru
аспирант хирургического отд-ния абдоминальной онкологии торакоабдоминального отд. ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

S N Nered

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation; Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. отд-ния абдоминальной онкологии торакоабдоминального отд. ФГБУ РОНЦ им. Н.Н.Блохина, доц. каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

P P Arkhiri

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation; Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

канд. мед. наук, врач-хирург отд-ния абдоминальной онкологии торакоабдоминального отд. ФГБУ РОНЦ им. Н.Н.Блохина, ассистент каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

M P Nikulin

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд-ния абдоминальной онкологии торакоабдоминального отдела ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

I S Stilidi

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation; Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

чл.-кор. РАН, д-р мед. наук, проф., рук. отд-ния абдоминальной онкологии торакоабдоминального отд. ФГБУ РОНЦ им. Н.Н.Блохина, проф. каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

References

  1. Demetri G.D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002; 38 (Suppl. 5): 52-S59.
  2. Duensing A, Medeiros F, Mc Conarty B. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs). Oncogene 2004; 23: 3999-4006.
  3. Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689-95.
  4. Demetri G.D, von Mehren M, Blanke C.D.N. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472-80.
  5. Huizinga J.D. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 1999; 47: 239-47.
  6. Tarn C, Skorobogatko Y.V, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477-86.
  7. Verweij J,Casali P.G, Zalcberg J et al. Progression - free survival in gastrointestinal stromal tumours withhigh - doseimatinib: randomized trial. Lancet 2004; 364: 1127-34.
  8. Blanke C.D, Rankin C, Demetri G.D et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosinekinase: S0033. J Clin Oncol 2008; 26: 626-32.
  9. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations In gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743-9.
  10. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of Patients with initially inoperable and/or metastatic gastrointestinal Stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304-11.
  11. Raut C.P, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-31.
  12. Blanke C.D, Demetri G.D, von Mehren M et al. Long - term results from a randomized phase II trial of standard - versus higher - dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5.
  13. Bonvalot S, Eldweny H, Pechoux C.L et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596-603.
  14. Raut C.P, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-31.
  15. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304-11.
  16. Andtbacka R.H, Ng C.S, Scaife C.L et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
  17. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular - targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341-6.
  18. De Matteo R.P, Maki R.G, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-52.
  19. Mearadji A, den Bakker M.A, van Geel A.N et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs 2008; 19: 607-12.
  20. Mussi C, Ronellenfitsch U, Jakob J et al. Post - imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-8.
  21. Ng E.H, Pollock R.E, Munsell M.F et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77.
  22. Yeh C.N, Chen T.W, Tseng J.H et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102: 599-603.
  23. Ronald Tielen, Cornelis Verhoef, Frits van Coevorden. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. http://www.wjso.com/content/10/1/111
  24. De Matteo R.P, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540-7.
  25. Demetri G.D, von Mehren M, Blanke C.D et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472-80.
  26. Van Oosterom A.T, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421-3.
  27. Verweij J, Casali P.G, Zalcberg J et al. Progression - free survival in gastrointestinal stromal tumours with high - dose imatinib: Randomised trial. Lancet 2004; 364: 1127-34.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies